An optimized b-value sampling for the quantification of interstitial fluid using diffusion-weighted MRI, a genetic algorithm approach

PurposeMulti-b-value diffusion-weighted MRI techniques can simultaneously measure the parenchymal diffusivity, microvascular perfusion, and a third, intermediate diffusion component. This component is related to the interstitial fluid in the brain parenchyma. However, simultaneously estimating three diffusion components from multi-b-value data is difficult and has strong dependence on SNR and chosen b-values. As the number of acquired b-values is limited due to scanning time, it is important to know which b-values are most effective to be included. Therefore, this study evaluates an optimized b-value sampling for interstitial fluid estimation. MethodThe optimized b-value sampling scheme is determined using a genetic algorithm. Subsequently, the performance of this optimized sampling is assessed by comparing it with a linear, logarithmic, and previously proposed sampling scheme, in terms of the RMS error (RMSE) for the intermediate component estimation. The in vivo performance of the optimized sampling is assessed using 7T data with 101 equally spaced b-values ranging from 0 to 1000 s/mm(2). In this case, the RMSE was determined by comparing the fit that includes all b-values. ResultsThe optimized b-value sampling for estimating the intermediate component was reported to be [0, 30, 90, 210, 280, 350, 580, 620, 660, 680, 720, 760, 980, 990, 1000] s/mm(2). For computer simulations, the optimized sampling had a lower RMSE, compared with the other samplings for varying levels of SNR. For the in vivo data, the voxel-wise RMSE of the optimized sampling was lower compared with other sampling schemes. ConclusionThe genetic algorithm-optimized b-value scheme improves the quantification of the diffusion component related to interstitial fluid in terms of a lower RMSE

Assessment of microvascular rarefaction in human brain disorders using physiological magnetic resonance imaging

Cerebral microvascular rarefaction, the reduction in number of functional or structural small blood vessels in the brain, is thought to play an important role in the early stages of microvascular related brain disorders. A better understanding of its underlying pathophysiological mechanisms, and methods to measure microvascular density in the human brain are needed to develop biomarkers for early diagnosis and to identify targets for disease modifying treatments. Therefore, we provide an overview of the assumed main pathophysiological processes underlying cerebral microvascular rarefaction and the evidence for rarefaction in several microvascular related brain disorders. A number of advanced physiological MRI techniques can be used to measure the pathological alterations associated with microvascular rarefaction. Although more research is needed to explore and validate these MRI techniques in microvascular rarefaction in brain disorders, they provide a set of promising future tools to assess various features relevant for rarefaction, such as cerebral blood flow and volume, vessel density and radius and blood-brain barrier leakage

Evaluation of miCRovascular rarefaction in vascUlar Cognitive Impairment and heArt faiLure (CRUCIAL): Study protocol for an observational study

Introduction: Microvascular rarefaction, the functional reduction in perfused microvessels and structural reduction of microvascular density, seems to be an important mechanism in the pathophysiology of small blood vessel related disorders including vascular cognitive impairment (VCI) due to cerebral small vessel disease and heart failure with preserved ejection fraction (HFpEF). Both diseases share common risk factors including hypertension, diabetes mellitus, obesity, and ageing; in turn, these co-morbidities are associated with microvascular rarefaction. Our consortium aims to investigate novel non-invasive tools to quantify microvascular health and rarefaction in both organs, as well as surrogate biomarkers for cerebral and/or cardiac rarefaction (via sublingual capillary health, vascular density of the retina, and RNA content of circulating extracellular vesicles), and to determine whether microvascular density relates to disease severity.Methods/design: The clinical research program of CRUCIAL consists of four observational cohort studies. We aim to recruit 75 VCI patients, 60 HFpEF patients, 60 patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement as a pressure overload HFpEF model, and 200 elderly participants with mixed comorbidities to serve as controls. Data collected will include medical history, physical examination, cognitive testing, advanced brain and cardiac MRI, ECG, echocardiography, sublingual capillary health, optical coherence tomography angiography (OCTa), extracellular vesicles RNA analysis and myocardial remodelling-related serum biomarkers. The AS cohort undergoing surgery will also have myocardial biopsy for histological microvascular assessment. Discussion: CRUCIAL will examine the pathophysiological role of microvascular rarefaction in VCI and HFpEF using advanced brain and cardiac MRI techniques. Furthermore, we will investigate surrogate biomarkers for non-invasive, faster, easier, and cheaper assessment of microvascular density since these are more likely to be disseminated into widespread clinical practice. If microvascular rarefaction is an early marker of developing small vessel diseases, then measuring rarefaction may allow pre-clinical diagnosis, with implications for screening, risk stratification, and prevention. Further knowledge of the relevance of microvascular rarefaction and its underlying mechanisms may provide new avenues for research and therapeutic targets